Key facts
- It has raised $274.0M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($92.0M) in Oct 2024.
- Notable investors include RA Capital Management, ARCH Venture Partners, Bristol-Myers Squibb, Atlas Venture, Takeda Ventures — 11 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Be Biopharma
Funding rounds
2 roundsAbout Be Biopharma
Developer of engineered B-cell medicines intended to transform treatment for patients with serious diseases. The company's drugs address major hurdles of cell and gene therapies and are durable, re-enable, and can be administered without toxic conditioning, enabling healthcare professionals to treat diseases like cancer, autoimmune conditions, and enzyme deficiency while providing targeted, effective care for patients.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Employees
- 84
- Website
- be.bio/
- Ownership
- Privately Held (backing)
Be Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Be Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Be Biopharma in its N-PORT filings yet. We sweep new filings monthly.